Transient monocular visual impairment as an initial symptom of COVID-19 infection in an individual with multiple sclerosis receiving teriflunomide
- 3 February 2021
- journal article
- research article
- Published by Springer Nature in Neurological Sciences
- Vol. 42 (5) , 1661-1664
Abstract
In December 2019, coronavirus disease 2019 (COVID-19) emerged in Wuhan and rapidly spread throughout China. Since the outbreak of the pandemic, in addition to the well-known COVID-19 symptoms, various neurological symptoms have been also described in patients with COVID-19. Here, we report an unusual presentation of COVID-19 infection in a teriflunomide-treated individual with multiple sclerosis (MS) who did not interrupt teriflunomide treatment during the infection. The course of the infection was mild in this case as in other reported teriflunomide-treated individuals with COVID-19. COVID-19’s presentation may be unusual in people with MS (pwMS). It can also be concluded that teriflunomide may be considered a safe disease-modifying treatment option during the pandemic.Keywords
This publication has 18 references indexed in Scilit:
- Mild COVID‐19 infection in a group of teriflunomide‐treated patients with multiple sclerosisJournal of Neurology, 2020
- Asymptomatic optic nerve lesionsNeurology, 2020
- COVID-19 Immunopathology and the Central Nervous System: Implication for Multiple Sclerosis and Other Autoimmune Diseases with Associated DemyelinationBrain Sciences, 2020
- Central nervous system manifestations of COVID-19: A systematic reviewJournal of the Neurological Sciences, 2020
- Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapseJournal of Neurology, 2020
- COVID-19 virus may have neuroinvasive potential and cause neurological complications: a perspective reviewJournal of NeuroVirology, 2020
- Neurology in the time of COVID-19Journal of Neurology, Neurosurgery & Psychiatry, 2020
- Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trialsMultiple Sclerosis Journal, 2019
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteriaThe Lancet Neurology, 2018
- Teriflunomide and Its Mechanism of Action in Multiple SclerosisDrugs, 2014